Fosdagrocorat

Drug Profile

Fosdagrocorat

Alternative Names: PF-04171327; PF-4171327

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Amides; Anti-inflammatories; Antirheumatics; Phenanthrenes; Pyridines; Small molecules
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 May 2016 Discontinued - Phase-II for Rheumatoid arthritis in USA, Czech Republic, China, Hungary, South Korea, Russia, Serbia, Singapore, Slovakia, Spain, Turkey, Ukraine, Taiwan, Bulgaria, Colombia, Germany, India, Malaysia, Mexico, Poland, Romania, South Africa (PO) (Pfizer pipeline, May 2016)
  • 03 Sep 2015 Phase II development of fosdagrocorat is ongoing
  • 01 Jun 2014 Pfizer completes a phase II trial in Rheumatoid arthritis in US, Bulgaria, Colombia, the Czech Republic, Germany, Hungary, India, South Korea, Malaysia, Mexico, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Spain and the Ukraine (NCT01393639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top